DIA Biosimilars 2013

SAFE-BioPharma Association

Trifecta Clinical, SAFE-BioPharma partner

Friday, September 20, 2013 10:37 AM

Trifecta Clinical, a global clinical technology solutions provider, has partnered with SAFE-BioPharma to implement the SAFE-BioPharma digital identity and signature standard across its application platforms. The digital identity and signature standard provides standardized, high-assurance identity trust for cyber-transactions across the biopharmaceutical and healthcare sectors. This will accelerate the adoption of standards-based identity management, enhancing security, quality and compliance. The company also joined SAFE-BioPharma Association’s Vendor Partner Program.

More... »

Cenduit: Now with Patient Reminders

EMA now accepting Safe-BioPharma digital signatures on eSubmissions

Friday, September 6, 2013 02:53 PM

Beginning this month, SAFE-BioPharma digital signatures will be accepted by the European Medicines Agency (EMA).  

More... »

CRF Health – eCOA Forum

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »

Peter Alterman named COO of SAFE-BioPharma

Monday, August 13, 2012 03:13 PM

Peter Alterman, Ph.D., who held numerous senior information security positions within the U.S. federal government, has been named chief operating officer of SAFE-BioPharma Association, the strategic, non-profit collaboration responsible for the global SAFE-BioPharma digital identity and digital signature standard used in the life science and healthcare sectors.
 
Alterman recently retired after 33 years of government service where, most recently, he was senior advisor to the national program office of the National Strategy for Trusted Identities in Cyberspace (NSTIC), NIST. Before that he served as senior advisor to the NIH CIO for Strategic Initiatives, Assistant CIO for e-authentication at the National Institutes of Health and chair of the U.S. Federal PKI Policy Authority. His role in Internet technology started in 1989 as a member of the Federal Research Internet Coordinating Committee.
  
In addition to responsibilities for a variety of association management functions, Alterman will serve as SAFE-BioPharma’s primary liaison with the FDA and other global regulatory authorities and represent the association’s interests on global standards and policy bodies.

More... »

Pfizer’s Karen Bien elected to board of SAFE-BioPharma

Friday, June 29, 2012 09:57 AM

Karen Bien, director of business technology on Pfizer’s acquisition, collaboration and divestiture team, has been elected to the board of directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard for the life science and healthcare sectors.

More... »

Liaison Tech partners with SAFE-BioPharma Association

Monday, February 13, 2012 03:06 PM

Liaison Technologies, a global provider of secure cloud-based integration and data management services, has partnered with the SAFE-BioPharma Association.

More... »

HighQ partners with SAFE-BioPharma

Wednesday, December 7, 2011 12:23 PM

London-based HighQ has formed a vendor partnership with the SAFE-BioPharma Association. Companies within the global pharmaceutical and biotechnology industry use the SAFE-BioPharma standard in FDA Title 21 CFR part 11 compliant processes for signing SOPs, quality and compliance documentation, research and development documentation, corporate compliance documents and more.

More... »

Savara joins SAFE-BioPharma

Tuesday, November 22, 2011 11:25 AM
Savara Pharmaceuticals, an inhalation drug development company, has joined SAFE-BioPharma Association. SAFE-BioPharma manages the SAFE-BioPharma digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

More... »

Taigle becomes SAFE-BioPharma partner

Thursday, October 20, 2011 01:21 PM

Taigle has become a vendor partner of SAFE-BioPharma, the non-profit that manages the SAFE-BioPharma digital identity and signature standard for the biopharmaceutical and healthcare industries. The SAFE-BioPharma standard allows its member companies to meet security and confidentiality needs specific to the life sciences.

More... »

SAFE-BioPharma Signing up Sites, CROs

Wednesday, June 23, 2010 08:48 AM

Contract research organizations (CROs) and investigative sites have begun to adopt SAFE-BioPharma digital identities, which are already widely used by biopharmaceutical companies, in order to sign contracts and other clinical trial documents electronically.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs